Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

778

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
SepsisSepsis-induced CoagulopathyNafamostat Mesilate
Interventions
DRUG

Nafamostat mesilate

Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)

DRUG

5% glucose

Add 50ml of 5% glucose into a 50ml syringe

All Listed Sponsors
collaborator

Tianjin Third Central Hospital

OTHER

collaborator

Tianjin Medical University General Hospital

OTHER

collaborator

Shanxi Provincial People's Hospital

OTHER_GOV

collaborator

Shanxi Bethune Hospital

OTHER

collaborator

Hohhot First Hospital

UNKNOWN

collaborator

The First Bethune Hospital Jilin University

UNKNOWN

collaborator

Northern Jiangsu People's Hospital

OTHER

collaborator

The Affiliated Hospital of Nantong University

UNKNOWN

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

The First Affiliated Hospital of Suzhou Medical

UNKNOWN

collaborator

Anhui Provincial Hospita

UNKNOWN

collaborator

Zhejiang Hospital

OTHER

collaborator

Zhejiang Provincial People's Hospital

OTHER

collaborator

The First Affiliated Hospital of Ningbo

UNKNOWN

collaborator

The First Affiliated Hospital of Wenzhou

UNKNOWN

collaborator

The Jiangxi Provincial People's Hospital

UNKNOWN

collaborator

First Affiliated Hospital of Gannan Medical University

OTHER

collaborator

The Second Affiliated Hospital Xi'an Jiaotong

UNKNOWN

collaborator

LanZhou University

OTHER

collaborator

The First Affiliated Hospital of Xinjiang

UNKNOWN

collaborator

First Affiliated Hospital of Xinjiang Medical University

OTHER

collaborator

Tongji Medical College of Huazhong University

UNKNOWN

collaborator

The Second Hospital University of South China

OTHER

collaborator

The Fourth Affiliated Hospital of China Medical

UNKNOWN

collaborator

The First Affiliated Hospital of Liaoning

UNKNOWN

collaborator

Genertec Liaoyou Gem Flower Hospital

UNKNOWN

collaborator

The Tenth People's Hospital of Shenyang

UNKNOWN

collaborator

The Sixth People's Hospital of Shenyang

OTHER

collaborator

Dalian NO.3 People's Hospital

UNKNOWN

collaborator

Benxi Cental Hospital

OTHER

collaborator

Liaoyang City Central Hospital

UNKNOWN

collaborator

Huludao central hospital

UNKNOWN

lead

Xu Li

OTHER

NCT06078839 - Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy | Biotech Hunter | Biotech Hunter